{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:08:13Z","timestamp":1785168493264,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA247648"],"award-info":[{"award-number":["U24CA247648"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105569","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:19:35Z","timestamp":1757629175000},"page":"105569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-2413","authenticated-orcid":false,"given":"A.M.","family":"Schram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-2902","authenticated-orcid":false,"given":"Q.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9834-2071","authenticated-orcid":false,"given":"J.","family":"Silber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gavriliuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-0536","authenticated-orcid":false,"given":"E.E.","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105569_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105569_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"7092","key":"10.1016\/j.esmoop.2025.105569_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105569_bib4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105569_bib5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"5670","key":"10.1016\/j.esmoop.2025.105569_bib6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105569_bib7","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","article-title":"The biology and clinical relevance of the PTEN tumor suppressor pathway","volume":"22","author":"Sansal","year":"2004","journal-title":"J Clin Oncol"},{"issue":"41","key":"10.1016\/j.esmoop.2025.105569_bib8","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/onc.2008.247","article-title":"The PTEN-PI3K pathway: of feedbacks and cross-talks","volume":"27","author":"Carracedo","year":"2008","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105569_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1389450114666140106100909","article-title":"Therapeutic targeting of cancers with loss of PTEN function","volume":"15","author":"Dillon","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"Pt 3","key":"10.1016\/j.esmoop.2025.105569_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1242\/jcs.022459","article-title":"The nuclear affairs of PTEN","volume":"121","author":"Planchon","year":"2008","journal-title":"J Cell Sci"},{"issue":"41","key":"10.1016\/j.esmoop.2025.105569_bib11","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1038\/onc.2008.241","article-title":"PTEN: a new guardian of the genome","volume":"27","author":"Yin","year":"2008","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105569_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105569_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105569_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105569_bib15","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1073\/pnas.0702507104","article-title":"Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity","volume":"104","author":"Saal","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105569_bib16","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer","volume":"68","author":"Stemke-Hale","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105569_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-011-1572-5","article-title":"Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer","volume":"128","author":"Razis","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105569_bib18","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","article-title":"PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer","volume":"177","author":"Esteva","year":"2010","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105569_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2009.27.7814","article-title":"Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2\u2013overexpressing locally advanced breast cancers","volume":"29","author":"Dave","year":"2011","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105569_bib20","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105569_bib21","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3748\/wjg.v18.i21.2712","article-title":"Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis","volume":"18","author":"Shen","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105569_bib22","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1200\/JCO.2008.20.2796","article-title":"PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer","volume":"27","author":"Loupakis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7205","key":"10.1016\/j.esmoop.2025.105569_bib23","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","article-title":"Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis","volume":"454","author":"Jia","year":"2008","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105569_bib24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/2159-8290.CD-13-0873","article-title":"PTEN-deficient tumors depend on AKT2 for maintenance and survival","volume":"4","author":"Chin","year":"2014","journal-title":"Cancer Discov"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105569_bib25","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.0802655105","article-title":"PTEN-deficient cancers depend on PIK3CB","volume":"105","author":"Wee","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105569_bib26","doi-asserted-by":"crossref","first-page":"11002","DOI":"10.1073\/pnas.1005642107","article-title":"A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice","volume":"107","author":"Lee","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105569_bib27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.18632\/oncotarget.27503","article-title":"Targeting PI3K\u03b2 alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss","volume":"11","author":"Owusu-Brackett","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105569_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-14-0406","article-title":"Inhibition of PI3K\u03b2 signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel","volume":"14","author":"Hancox","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105569_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063833","article-title":"Characterization of a tumor-associated activating mutation of the p110\u03b2 PI 3-kinase","volume":"8","author":"Dbouk","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105569_bib30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/onc.2015.173","article-title":"Oncogenic activation of the PI3-kinase p110\u03b2 isoform via the tumor-derived PIK3C\u03b2(D1067V) kinase domain mutation","volume":"35","author":"Pazarentzos","year":"2016","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105569_bib31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2025.105569_bib32","article-title":"Functional characterization of a novel somatic oncogenic mutation of PIK3CB","volume":"2","author":"Whale","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105569_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105569_bib34","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-21-3087","article-title":"A phase I study investigating AZD8186, a potent and selective inhibitor of PI3K\u03b2\/\u03b4, in patients with advanced solid tumors","volume":"28","author":"Choudhury","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105569_bib35","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105569_bib36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ab.2003.09.038","article-title":"Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"324","author":"Baker","year":"2004","journal-title":"Anal Biochem"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105569_bib37","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.1994.12.6.1232","article-title":"Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105569_bib38","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO;2-Y","article-title":"Phase II trial of a 75-mg\/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer","volume":"75","author":"Miller","year":"1995","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105569_bib39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/09622802231224631","article-title":"Dynamic prediction of survival using multivariate functional principal component analysis: a strict landmarking approach","volume":"33","author":"Gomon","year":"2024","journal-title":"Stat Methods Med Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105569_bib40","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105569_bib41","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105569_bib42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105569_bib43","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1158\/1078-0432.CCR-0842-03","article-title":"Comparative pharmacokinetics of weekly and every-three-weeks docetaxel","volume":"10","author":"Baker","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105569_bib44","first-page":"1037","article-title":"Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion","volume":"53","author":"Extra","year":"1993","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105569_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1349-7006.2006.00166.x","article-title":"Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients","volume":"97","author":"Minami","year":"2006","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105569_bib46","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2005.03.082","article-title":"Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly","volume":"23","author":"ten Tije","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105569_bib47","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105569_bib48","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105569_bib49","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2022.40.16_suppl.5052","article-title":"Phase I\/II study of the selective PI3K\u03b2 inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105569_bib50","article-title":"Correction to: AZD8186 in combination with paclitaxel in patients with advanced gastric cancer: results from a phase Ib\/II study (KCSG ST18-20)","volume":"29","year":"2024","journal-title":"Oncologist"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:59:23Z","timestamp":1772895563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014383"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105569","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105569"}}